1. Efficacy of Atorvastatin for Achieving Cholesterol Targets After LDL-Cholesterol Based Dose Selection in Patients With Type 2 Diabetes
- Author
-
Miguel Berzosa-Sanchez, Eva Sanchez-Ballester, Raquel Albalat-Galera, Agustín Herrera-Ballester, and Juan Carlos Ferrer-García
- Subjects
Adult ,Male ,medicine.medical_specialty ,Time Factors ,Statin ,medicine.drug_class ,Atorvastatin ,Urology ,Hyperlipidemias ,Type 2 diabetes ,Pharmacology ,chemistry.chemical_compound ,High-density lipoprotein ,medicine ,Clinical endpoint ,Humans ,Pyrroles ,Pharmacology (medical) ,In patient ,Triglycerides ,Aged ,Aged, 80 and over ,Dose-Response Relationship, Drug ,Cholesterol ,business.industry ,Cholesterol, HDL ,nutritional and metabolic diseases ,Cholesterol, LDL ,Middle Aged ,medicine.disease ,Treatment Outcome ,Diabetes Mellitus, Type 2 ,chemistry ,Heptanoic Acids ,Feasibility Studies ,Female ,lipids (amino acids, peptides, and proteins) ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,Cardiology and Cardiovascular Medicine ,business ,Dyslipidemia ,medicine.drug - Abstract
We analyzed the feasibility of an intensive lipid-lowering strategy based on a starting dose of atorvastatin according to baseline and target low-density lipoprotein cholesterol (LDL-C) level (
- Published
- 2008
- Full Text
- View/download PDF